Akari Therapeutics Targets Mid — 2027 Start for AKTX — 101 Phase 1 Trial

Akari Therapeutics is advancing AKTX-101 through preclinical safety studies and manufacturing, targeting Phase 1 clinical development in mid-2027. Its PH1 payload is designed to disrupt RNA splicing in cancer cells, offering a different approach from commonly used ADC payloads. Clinical data already presented at major medical conferences showed no benefit from sequential ADC treatments using the same payload class following relapse. Potential strategic partnerships and payload licensing remain under discussion as the developer explores a broader ADC pipeline. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via (Ref. ID: 202610150920PRIMZONEFULLFEED9846075) on October 15, 2026, and is solely responsible for the information contained therein. (C)